Risultati ricerca per “Test C-S4CS-2408 Preparation 🤢 C-S4CS-2408 Braindump Pdf 😘 Study C-S4CS-2408 Center 🖌 Search for ➡ C-S4CS-2408 ️⬅️ on [ www.pdfvce.com ] immediately to obtain a free download 💮Latest C-S4CS-2408 Exam Labs”
Detectnet™
Solar-Recur: A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Men with Biochemical Recurrence of Prostate Cancer
Solar-Stage: A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection
Ultratag™ RBC
Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency
Kit for the Preparation of Technetium Tc99m Sestamibi Injection
Ultratag™ RBC
Kit for the Preparation of Technetium Tc 99m Sestamibi Injection
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
Curium U.S. invoice terms and conditions of sale
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.
Technescan MAG3™
Ioflupane I 123 Injection
Nuclear medicine education
Welcome customers Thank you for visiting our Nuclear Medicine Education website. Through this website we strive to provide a robust variety of Continuing Education (CE) programs relevant to the Nuclear Medicine Technologist. All courses are structured in a self-paced learning format, conveniently accessible 24 hours a day, 7 days a week, and include course assessments […]
Octreoscan™
NRG and Curium Sign Multi-Year Isotope Production Contract
Curium Announces Approval of PulmotechTM MAA (kit for the preparation of technetium Tc 99m albumin aggregated injection) by the U.S. Food and Drug Administration
Indium In 111 Chloride Sterile Solution
Ultra-Technekow™ V4
Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T
Ultra-Technekow™ V4
Octreoscan™
Risorse
RadioMedix and Curium Announce copper Cu 64 dotatate injection Was Granted Priority Review by the U.S. FDA
Curium Expands Nuclear Medicine Offerings, Announces U.S. Availability of Xenon Xe 133 Gas
Curium Acquires Austrian Radiopharmaceuticals Company IASON
Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
Technescan™ PYP™
Curium receives marketing authorization in the EU for Pylclari™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
Curium announces exclusive distribution agreement in Switzerland with b.e. Imaging for PYLCLARI™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
Technescan™ HDP
Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial
Pulmotech™ MAA
Technescan MAG3™
Curium Prague, Czech Republic
RadioMedix and Curium Announce FDA Filing of copper Cu 64 dotatate injection New Drug Application
Curium Announces Revised Pricing for Technescan MAG3TM (kit for the preparation of technetium Tc 99m mertiatide)
Curium’s Customers to benefit from Mo-99 Production restart
Curium announces license and development agreement with Lantheus for AI-based PSMA PET software in Europe
Curium to Expand Noblesville Facility’s Workforce
Home
Prodotti europei
Curium e RadioMedix annunciano un esclusivo accordo internazionale per lo sviluppo di 64Cu-Dotatate
Curium Is the First North American Manufacturer Offering Exclusively 100% LEU Generators
Sodium Iodide I-123 Capsules
Curium to become major player in the supply on non carrier added Lu-177
Cosa facciamo
Xenon Xe 133 Gas
RadioMedix e Curium annunciano FDA Fast Track Designation per 64Cu-Dotatate.
Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99
Sicurezza dei farmaci
Termini di utilizzo
Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczacibaşi-Monrol
Progenics e Curium annunciano una collaborazione europea per lo sviluppo dell’agente di rilevamento del cancro alla prostata PyL™
Curium Acquires Finnish Radiopharmaceuticals Company MAP Medical Technologies Oy
Curium Acquires Zevacor Molecular Strengthening Its PET Portfolio
Curium Announces Drug Master File and Active Substance Master File for Germanium-68 in the U.S. and Europe
Gallium Citrate Ga 67 Injection
Curium e PIUR IMAGING annunciano una partnership per l’imaging tiroideo in Germania per abilitare soluzioni di ecografia 3D tomografica
Curium enhances its position in the French PET market with the completion of the acquisition of Cyclopharma’s French commercial and manufacturing operations
Xenotron™ I
RadioMedix & Curium Announce CMS Transitional Pass-Through Status for Detectnet™ (copper Cu 64 dotatate injection)
RadioMedix & Curium Announce Permanent HCPCS Code for Detectnet™ (copper Cu 64 dotatate injection)
RadioMedix & Curium Announce Simplified Coding for Detectnet™ (copper Cu 64 dotatate injection)
Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T
ERtracER Solution for Injection
Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO
Curasight and Curium announce global partnership for uTRACE® in prostate cancer
APhA Annual Meeting & Exposition
From March 23-25, we will be attending the 9th edition of Journées Francophones de Médecine Nucléaire (JFMN) at the Belfri de Montrouge, in the Paris region, France. Meet Curium team at booth 45B and attend our symposium presentation to gain insights into our multiomic approach to patient care. Symposium Presentation Speakers: PR.PY. SALAÜN, Dépistage de […]
30 Years in NETs
Contatti
Online Ordering (Dublin, Ireland)
Neuraceq
Un messaggio da Curium sul COVID-19 e le nostre azioni
BNMS – British Nuclear Medicine Society
From March 23-25, we will be attending the 9th edition of Journées Francophones de Médecine Nucléaire (JFMN) at the Belfri de Montrouge, in the Paris region, France. Meet Curium team at booth 45B and attend our symposium presentation to gain insights into our multiomic approach to patient care. Symposium Presentation Speakers: PR.PY. SALAÜN, Dépistage de […]